Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Phase 3

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Dovitinib
Drug: Sorafenib

First Posted Date: 2010-10-18

Last Posted Date: 2015-12-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 564

Registration Number: NCT01223027

Locations: 🇺🇸
Deke Slayton Cancer Center Deke Slayton Cancer Center (2), Webster, Texas, United States
🇺🇸
University of Kansas Cancer Center Univ of KS, Kansas City, Kansas, United States
🇺🇸
Rockwood Clinic Spokane Location, Spokane, Washington, United States

and more 32 locations

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Nilotinib, interferon-alfa

First Posted Date: 2010-10-14

Last Posted Date: 2015-05-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT01220648

Locations: 🇩🇪
Novartis Investigative Site, Leipzig, Germany

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Phase 1

Completed

Conditions: Estrogen Receptor Positive Breast Cancer
Advanced Solid Tumors With an Alteration of the PIK3CA Gene

Interventions: Drug: BYL719
Drug: Fulvestrant

First Posted Date: 2010-10-13

Last Posted Date: 2020-09-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 221

Registration Number: NCT01219699

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
🇺🇸
Vanderbilt Univeristy SC, Nashville, Tennessee, United States

and more 3 locations

A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer

Phase 1

Completed

Conditions: Locally Advanced Cervical Cancer

Interventions: Drug: everolimus

First Posted Date: 2010-10-08

Last Posted Date: 2015-04-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT01217177

Locations: 🇧🇷
Novartis Investigative Site, Rio de Janeiro, Brazil

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Phase 3

Completed

Conditions: Pathological Myopia

Interventions: Drug: Ranibizumab
Drug: Sham Ranibizumab
Drug: Verteporfin PDT
Drug: Sham verteporfin PDT

First Posted Date: 2010-10-08

Last Posted Date: 2014-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 277

Registration Number: NCT01217944

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Phase 4

Completed

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Drug: Fingolimod
Drug: Standard MS DMTs

First Posted Date: 2010-10-07

Last Posted Date: 2014-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1053

Registration Number: NCT01216072

Locations: 🇵🇷
Novartis Investigative Site, Guaynabo, Puerto Rico

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints

Phase 2

Completed

Conditions: Imatinib
CML

Interventions: Drug: high-dose imatinib

First Posted Date: 2010-10-07

Last Posted Date: 2021-03-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT01216085

Locations: 🇰🇷
Novartis Investigational Site, Seoul, Korea, Republic of

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients

Completed

Conditions: Neonatal Onset Multisystem Inflam Disease (NOMID)
Cryopyrin-associated Periodic Syndromes (CAPS)
Familial Cold Autoinflam Syn (FCAS)
Muckle-wells Syn (MWS)

First Posted Date: 2010-10-04

Last Posted Date: 2016-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 288

Registration Number: NCT01213641

Locations: 🇨🇭
Novartis Investigative site, Lausanne, Switzerland
🇺🇸
Little Rock Allergy and Asthma Clinic, Little Rock, Arizona, United States
🇺🇸
Rush Presbyterian - St. Lukes Medical Center, Chicago, Illinois, United States

and more 1 locations

An East Asian Study of LDE225

Phase 1

Completed

Conditions: Advanced Solid Tumor Cancers
Medulloblastoma
Basal Cell Carcinoma

Interventions: Drug: LDE225

First Posted Date: 2010-09-24

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT01208831

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

Phase 4

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: RAD001

First Posted Date: 2010-09-22

Last Posted Date: 2019-06-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 143

Registration Number: NCT01206764

Locations: 🇹🇳
Novartis Investigative Site, Sousse, Tunisia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy